What were Ajanta Pharma Ltd's latest quarterly results?
Ajanta Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +18.7%
- Revenue Growth YoY: +21.5%
- Operating Margin: 23.0%
Ajanta Pharma Ltd: Stock Analysis & Fundamentals
Updated this weekAjanta Pharma Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 36.0. ROE: 27.1%. This stock is not currently in the Nifty 500 momentum outperformers list.
Ajanta Pharma Ltd Key Facts
What's Happening
🌐FII stake decreased 0.6% this quarter
Key Numbers
Current Price
₹3,256
Dividend Yield
0.86%
Market Cap
40.7K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Ajanta Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Ajanta Pharma Ltd's current PE ratio?
Ajanta Pharma Ltd's current PE ratio is 36.0x.
- Current PE: 36.0x
- Market Cap: 40.7K Cr
- Dividend Yield: 0.86%
What is Ajanta Pharma Ltd's price-to-book ratio?
Ajanta Pharma Ltd's price-to-book ratio is 9.0x.
- Price-to-Book (P/B): 9.0x
- Book Value per Share: ₹362
- Current Price: ₹3256
Is Ajanta Pharma Ltd a fundamentally strong company?
Ajanta Pharma Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 35.0%
Is Ajanta Pharma Ltd debt free?
Ajanta Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹260 Cr
What is Ajanta Pharma Ltd's return on equity (ROE) and ROCE?
Ajanta Pharma Ltd's return ratios over recent years
- FY2024: ROCE 32.0%
- FY2025: ROCE 32.0%
- FY2026: ROCE 35.0%
Is Ajanta Pharma Ltd's cash flow positive?
Ajanta Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹529 Cr
- Free Cash Flow (FCF): ₹100 Cr
- CFO/PAT Ratio: 50% (adequate)
What is Ajanta Pharma Ltd's dividend yield?
Ajanta Pharma Ltd's current dividend yield is 0.86%.
- Dividend Yield: 0.86%
- Current Price: ₹3256
Who holds Ajanta Pharma Ltd shares — promoters, FII, DII?
Ajanta Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 66.3%
- FII (Foreign): 8.3%
- DII (Domestic): 18.4%
- Public: 7.1%
Is promoter holding increasing or decreasing in Ajanta Pharma Ltd?
Ajanta Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 66.3% (Mar 2026)
- Previous Quarter: 66.3% (Dec 2025)
- Change: 0.00% (stable)
Is Ajanta Pharma Ltd a new momentum entry or an established outperformer?
Ajanta Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Ajanta Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Ajanta Pharma Ltd may be worth studying
- Cash flow is positive — CFO ₹529 Cr
What is the investment thesis for Ajanta Pharma Ltd?
Ajanta Pharma Ltd investment thesis summary:
What is the future outlook for Ajanta Pharma Ltd?
Ajanta Pharma Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.